Literature DB >> 27558764

Atypical pityriasis rosea: clinical evaluation of 27 patients.

Fadime Kilinc1, Ayse Akbas1, Sertac Sener1, Akın Aktaş2.   

Abstract

BACKGROUND: Pityriasis rosea (PR) is a common, acute, self-limiting inflammatory skin disease. It can easily be recognized with its typical clinical presentation. However, unusual clinic presentations can cause difficulty in diagnosis. Up to now, not many atypical forms are reported.
OBJECTIVE: To determine the clinical characteristics of patients with atypical pityriasis rosea.
METHODS: A total of 27 cases, diagnosed as atypical PR by clinical and/or histopathological examination and applied to the outpatient clinic of dermatology department between the years 2007 and 2015 were analyzed retrospectively.
RESULTS: The ages of patients ranged from 2 to 59 years. Of these patients, 15 (55.6%) were male and 12 (44.4%) were female. The male-to-female ratio was 5-4. Five patients had papular, four patients had purpuric, three patients had vesicular, two patients had follicular, one patient had erythema multiforme-like and one patient had eczematous drug-induced atypical form of pityriasis rosea. There were 12 cases of localized, two cases of segmental pityriasis rosea. Four of the localized forms also had atypical morphology. Histopathological evaluation was required for diagnosis in 12 (44.4%) patients.
CONCLUSIONS: PR can appear in many different uncommon forms. Localization and skin rush can be misleading and diagnosis can be compelling.

Entities:  

Keywords:  Atypical; pityriasis rosea; purpuric

Mesh:

Year:  2016        PMID: 27558764     DOI: 10.1080/15569527.2016.1225217

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  1 in total

Review 1.  Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis.

Authors:  Milton Rodriguez-Zuniga; Natalie Torres; Herney Garcia-Perdomo
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.